Sensyne Health Launches First Digital Health Product in the U.S.
Summary
The U.S. launch of GDm-Health follows results from a randomised controlled trial conducted in the U.K. which demonstrated a reduction in caesarean sections, improvements in blood glucose monitoring adherence and higher satisfaction with care in women using GDm-Health. The roll out of the product in the U.S. will be led and overseen by Derek Baird who was recently appointed as Sensyne’s President, North America, and is responsible for driving the commercial development of the Company’s North American operations, building Sensyne’s presence in the U.S. and recruiting a U.S.-based business development team to work in collaboration with the Cognizant sales force. Entering the U.S. market will help pregnant women and clinicians in the U.S. manage diabetes in pregnancy, improving outcomes for both mothers and babies. We’re thrilled to make GDM-Health the first formal U.S. product launch and I look forward to more to come.” Sensyne Health plc is a clinical AI company that works in partnership with the NHS to improve patient care and accelerate the discovery and development of new medicines. GDm-Health is listed on NHS Digital’s Apps Library and has been the subject of a NICE (National Institute for Health and Care Excellence) Medtech innovation briefing [MIB131].